National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-15: The Prospects for Immunizing Against Shigella spp.." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
330
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

much like febrile seizures, except that they may occur in children with no or only low-grade fever and are prominent in children beyond the usual age of susceptibility to febrile seizures (2 to 3 years of age). Shigella bacteremia is more common than previously believed (especially with infection due to S. dysenteriae 1), has been detected in about 4 percent of patients with shigellosis admitted to the International Centre for Diarrhoeal Disease Research hospital in Bangladesh (ICDDR,B); and is associated with increased mortality (Struelens et al., 1985). Denudation of the intestinal epithelium increases the likelihood of gram-negative sepsis with other Enterobacteriaceae, especially in malnourished children, and has been documented in another 4 percent of hospitalized patients in Dhaka, Bangladesh. Denudation also dramatically increases the mortality rate.

Infection due to S. dysenteriae 1, and to a lesser extent S. flexneri, is associated with the development of a leukemoid reaction in 4 percent of hospitalized patients with shigellosis. Of these, one-third have evidence of hemolysis, one-third develop a hemolytic-uremic syndrome, and a few have transient uremia alone (Butler et al., 1984). The mortality rate for those with uncomplicated or complicated leukemoid reactions is about 20 percent. Bacteremia, leukemoid reactions, and hemolytic-uremic syndrome occur most often in poorly nourished children infected with S. dysenteriae 1, and are therefore more common in developing countries. Reactive arthritis with or without other classical manifestations of Reiter’s syndrome occurs more frequently with some types of shigella (e.g., S. flexneri) and is often seen in individuals positive for HLA-B27 histocompatibility antigen (Keusch, 1982).

PATHOGEN DESCRIPTION

Shigellas are classified in the family Enterobacteriaceae, tribe Escherichieae, and are closely related to E. coli. They are nonmotile, rod shaped, gram-negative bacteria that ferment glucose but do not produce gas. They are usually recognized first by their inability to ferment lactose, although S. sonnei is capable of late lactose fermentation. Selective media are employed for this purpose; these media contain bile salts to inhibit the growth of other fecal organisms and a dye indicator to demonstrate lactose fermentation. Although many media have been devised, some are highly inhibitory to shigellas, especially to S. dysenteriae 1. The genus is subdivided into four species, dysenteriae, flexneri, boydii, and sonnei. These have antigenically distinct lipopolysaccharides and may be recognized through the use of grouping antisera, as well as by biochemical reactions. There are multiple subtypes of S. dysenteriae, flexneri, and boydii and multiple colicin types of S. sonnei. Generally, however, a limited number of subtypes prevail in any given geographic area. Two major virulence attributes are involved in pathogenesis: the ability to invade epithelial cells, which is under polygenic control, and toxin production, the genetics of which are still uncertain.

Page
330
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)